Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angel M Cronin

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
Urology|December 8, 2009
Critical evaluation of perioperative complications in laparoscopic partial nephrectomyLucas Nogueira, Darren Katz, Rodrigo Pinochet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2010
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, RotterdamAndrew J Vickers, Angel M Cronin, Monique J Roobol, et al.
BMC Medicine|February 19, 2008
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyDavid Ulmert, Angel M Cronin, Thomas Björk, et al.
The Journal of Urology|June 16, 2010
Clinical outcomes of primary bladder carcinoma in situ in a contemporary seriesDaher C Chade, Shahrokh F Shariat, Guilherme Godoy, et al.
International Journal of Cancer|March 7, 2013
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 yearsAnders Christensson, Caroline Savage, Daniel D Sjoberg, et al.
Urology|January 29, 2014
Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimensRiina-Minna Väänänen, Hans Lilja, Leni Kauko, et al.
BJU International|July 16, 2011
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancerDavid J Gallagher, Angel M Cronin, Matthew I Milowsky, et al.
Prostate Cancer|June 6, 2014
Comparison of transperineal mapping biopsy results with whole-mount radical prostatectomy pathology in patients with localized prostate cancerDarren J Katz, Rodrigo Pinochet, Kyle A Richards, et al.
Health Services Research|July 26, 2018
Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at DiagnosisDebra P Ritzwoller, Paul A Fishman, Matthew P Banegas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomyMatthew Frank O'Brien, Angel M Cronin, Paul A Fearn, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
Urology|December 8, 2009
Critical evaluation of perioperative complications in laparoscopic partial nephrectomyLucas Nogueira, Darren Katz, Rodrigo Pinochet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2010
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, RotterdamAndrew J Vickers, Angel M Cronin, Monique J Roobol, et al.
BMC Medicine|February 19, 2008
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control studyDavid Ulmert, Angel M Cronin, Thomas Björk, et al.
The Journal of Urology|June 16, 2010
Clinical outcomes of primary bladder carcinoma in situ in a contemporary seriesDaher C Chade, Shahrokh F Shariat, Guilherme Godoy, et al.
International Journal of Cancer|March 7, 2013
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 yearsAnders Christensson, Caroline Savage, Daniel D Sjoberg, et al.
Urology|January 29, 2014
Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimensRiina-Minna Väänänen, Hans Lilja, Leni Kauko, et al.
BJU International|July 16, 2011
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancerDavid J Gallagher, Angel M Cronin, Matthew I Milowsky, et al.
Prostate Cancer|June 6, 2014
Comparison of transperineal mapping biopsy results with whole-mount radical prostatectomy pathology in patients with localized prostate cancerDarren J Katz, Rodrigo Pinochet, Kyle A Richards, et al.
Health Services Research|July 26, 2018
Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at DiagnosisDebra P Ritzwoller, Paul A Fishman, Matthew P Banegas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomyMatthew Frank O'Brien, Angel M Cronin, Paul A Fearn, et al.
Pageof 13